Van Niekerk C H, De Wet J I
Department of Paediatrics and Child Health, University of the Orange Free State, Bloemfontein, South Africa.
Clin Allergy. 1987 Nov;17(6):507-13. doi: 10.1111/j.1365-2222.1987.tb02046.x.
Forty patients with a well-documented history of seasonal hay fever and a positive skin-prick test specific to grass pollen, including Bermuda grass and maize pollen (Zea maize), were allocated randomly on a double-blind basis to receive either an oral mixed grass-maize pollen extract or a matched placebo during the 1981/1982 grass pollen season. After 12 months the code was broken and patients on placebo were transferred to active therapy while patients on active therapy continued with maintenance therapy for another 12 months during the 1982/1983 grass pollen season. The assessment of the effect of the orally administered grass-maize pollen extract was on the clinical symptoms. During the first year the patients on active therapy had significantly fewer hay fever symptoms during the summer months compared with the placebo group. During the second study year, with all patients on active therapy, both groups had markedly milder symptoms compared with the placebo group. Side-effects were negligible. This study concludes that oral immunotherapy with grass-maize pollen extract in grass pollen-sensitive seasonal hay fever patients is safe and effective.
40名有充分记录的季节性花粉症病史且对草花粉（包括百慕大草和玉米花粉（玉蜀黍））皮肤点刺试验呈阳性的患者，在1981/1982年草花粉季节被双盲随机分配，接受口服混合草 - 玉米花粉提取物或匹配的安慰剂。12个月后揭盲，安慰剂组患者转为接受积极治疗，而积极治疗组患者在1982/1983年草花粉季节继续维持治疗12个月。口服草 - 玉米花粉提取物效果的评估基于临床症状。在第一年，与安慰剂组相比，积极治疗组患者在夏季的花粉症症状明显更少。在第二项研究年度，所有患者都接受积极治疗，与安慰剂组相比，两组症状均明显减轻。副作用可忽略不计。本研究得出结论，对于对草花粉敏感的季节性花粉症患者，口服草 - 玉米花粉提取物进行免疫治疗是安全有效的。
